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a b s t r a c t
The evolution of hepatitis C virus (HCV) quasispecies in patients with HIV-1 coinfection is not fully
understood. The HCV-1a quasispecies heterogeneity was analyzed at inter and intra-host levels along
7.6 years in 21 coinfected patients that showed different virological and immunological responses to
highly active antiretroviral therapy (HAART). Two to nine serial samples were subjected to direct and
clonal sequence analyses of the envelope glycoprotein 2 (E2) gene. E2-based phylogenies, intra-host HCV
evolution and evolutionary rates, as well as dynamics of the quasispecies heterogeneity parameters were
evaluated. Bayesian coalescent phylogenies indicated complex evolutionary histories, revealing some
viral lineages that persisted along the follow up and others that were detectable at a single or some
sampling times, suggesting the occurrence of emergence–extinction cycles. HCV quasispecies underwent
very rapid evolution in HAART-treated patients (3.1102 sub/site/year) following the recovery of the
host immunocompetence irrespectively of the virological response to HAART.
& 2014 Elsevier Inc. All rights reserved.
Introduction
About 30% of HIV-1-infected individuals in the Western world
are coinfected with hepatitis C virus (HCV) (Potter et al., 2010;
Sherman et al., 2002). HIV-related immune suppression or
immune dysregulation is associated with accelerated liver disease
in individuals with HIV–HCV coinfection (Connoy et al., 2011; de
Ledinghen et al., 2008; Verma et al., 2006). Accordingly, patients
on highly active antiretroviral therapy (HAART) display slower
progression of HCV disease and reduced HCV-related mortality
rates (Pascual-Pareja et al., 2009).
At intra-host level, HCV exists as quasispecies deﬁned by several
closely related yet genetically distinct populations mainly because
of low viral RNA polymerase ﬁdelity (Bittar et al., 2013; Caraballo
Cortes et al., 2013). The mechanisms driving HCV quasispecies
diversiﬁcation are not completely understood. However, humoral
pressure on the envelope gene hypervariable region (E2-HVR)
seems to be involved in driving quasispecies evolution (Farci,
2011; Jackowiak et al., 2012; Mondelli et al., 1999). This genomic
region includes three domains namely the hypervariable region 1
(HVR1), which is located at the N-terminus of E2 (Weiner et al.,
1991), the second hypervariable cluster (HVR2) (Kato et al., 1992a,
1992b), and the third one (HVR3), which is positioned between
HVR1 and HVR2 (Troesch et al., 2006). In vitro experiments have
characterized three independent functional microdomains in HVR1
that play several critical roles for HCV cell entry (Guan et al., 2012).
The clinical relevance of the E2 genetic variation is also
uncertain, but decreased variability in HCV quasispecies over time
has been associated with more advanced liver disease (Chayama
and Hayes, 2011; Gretch et al., 1996; Lopez-Labrador et al., 2006).
Certain immunosuppressed states are associated with reduced
quasispecies heterogeneity (Feliu et al., 2004; Gray et al., 2012;
Kumar et al., 1994; Schramm et al., 2008). However, studies of
HCV/HIV-coinfected subjects have reported both increased
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(Sherman et al., 1996) and decreased (Shuhart et al., 2006)
quasispecies heterogeneity, compared to subjects with HCV infec-
tion alone. Similarly, HCV exhibits greater quasispecies variability
according to the magnitude of the immune pressure, as reﬂected
by HIV-infected individuals with higher CD4 cell counts (Neau
et al., 2003; Solmone et al., 2006) or delayed HIV disease progres-
sion (Lopez-Labrador et al., 2007). The effect of highly active
antiretroviral therapy (HAART) in HCV variability over time in
coinfected subjects is still controversial.
Viral population dynamics can be inferred by a phylogenies
combined with demographic and coalescence models (Pybus et al.,
2000). This approach, in combination with new and sensitive
methods for detecting selection pressures at the codon level
(Kosakovsky Pond and Frost, 2005), may better reveal the evolu-
tionary forces driving the viral heterogeneity in a single host
during the infection.
We investigated the long-term evolution of HCV before and
during HAART therapy in 21 HIV-coinfected patients to determine
the effect of HAART-responsiveness on viral dynamics. A long-
itudinal sampling strategy, spanning between 4 and 11 years
previous and during antiretroviral therapy, was combined with
phylogenetic methods to deﬁne the evolutionary relationships in
the HCV population and the role played by both HIV-replication
suppression and immunocompetence recovery in driving the long
term evolution of HCV quasispecies.
Results
Characterization of the study group
The study population involved 14 males and 7 females;
mean7SD age was 36.2776.6 years old. The length of the
longitudinal sampling analysis (mean7SD) was similar between
HAART responders (7.171.9 years), and HAART non-responders
(8.171.6 years). Among all patients, the median (IQR) CD4 T-cell
count was 397 (17–1384) cells/μl. Plasma HCV RNA was persis-
tently detected in all patients from the baseline throughout the
study, with a median (IQR) level of 5.85 (5.05–6.73) log UI/mL.
These levels were similar before and during HAART therapy, as
well as between therapy responders and non-responders. At
baseline, the median (IQR) HIV viral load among all patients was
4.6 (3.9–5.4) log copies/mL and no differences were observed
between group A (HAART-responders) and B (HAART non-respon-
ders) patients. Immunological restoration, which was deﬁned as
CD4 T-cell count increase more than 1.5 times from baseline to the
last sampling time under HAART (Bernini et al., 2011), was
observed in both groups of patients, although it was more
pronounced among HAART virological non-responders (group B)
(3.3-fold vs. 1.9-fold increase from baseline, respectively; Table 1).
Analyses based on direct E2 nucleotide sequences
Phylogenetic analysis of the 102 E2 master sequences obtained
from all sampling times conﬁrmed that all these sequences belonged
to genotype 1a. Furthermore, this analysis allowed the recovery of
several monophyletic sequence groups that were consistent with the
patient source, showing that they were more closely related to each
other than to other patient isolates, and indicating the absence of
cross-contamination (Fig. 1). No recombinant sequences were found
after the GARD genetic algorithm analysis.
The comparison of the 102 partial E2 sequences (aa 364–554)
obtained from the 21 patients at different time-points showed that
amino acid mutations were located mainly at HVR1, and to a lesser
extent at HVR3 (Fig. 2; Supplementary Table 1). The three functional
microdomains of HVR1 showed dissimilar amino acid patterns.
All patients exhibited amino acid variations at the second micro-
domain, while the presence of changes in the ﬁrst and third
microdomains was less prevalent. The three neutralization epitopes,
which involve both linear and conformational protein structures,
showed many amino acid substitutions. These changes appeared
frequently at well deﬁned positions, i.e. I414V, E431A/D, L438V/I,
A531E/S/D, D533A/E. However, their presence did not appear to be
related with neither HCV plasma viral load nor CD4 T-cell counts.
All N-glycosilation sites were conserved. In addition, by using the
sequence logo representation, we compared the relative amino acid
positional frequencies within the E2 set of proteins for each group
of patients according to HAART-response. It was primarily used to
identify the highly conserved positions in the E2 amino acid
sequences (e.g. E384; T388; W417; C432). Likewise, the comparison
between baseline and latest sampling time sequence logos showed
the similarities (e.g. Cysteine residues at positions 432, 439) and the
differences (e.g. amino acid relative frequencies at positions from
390 to 405) between the two types of sequences, which were
clearly visible in the sequence logos (Fig. 2).
When comparing the mean HCV genetic distance, complexity
and immune pressure (measured as dN/dS ratio) between the two
groups of patients, values were signiﬁcantly higher in group B
(HAART virological non-responders) than in group A during the
follow-up (Table 2).
Table 1
Demographic, immunologic, and virologic characteristics of the patients studied.
Characteristic HAART Group A (n¼12) HAART-responders
[Pat1, 2, 5, 8, 13, 14, 17, 20, 21, 26, 27, 28]
Group B (n¼9) HAART-non-responders
[Pat3, 6, 7, 9, 18, 23,24, 25,29]
Pn
Age, median (IQR) 42 (39.5–46.7) 43 (40.5–47.7) NS
Sex (male/female) 8/4 6/3 NS
CD4þ T-cell count, median (IQR), cells/mm3 Pre 207 (111–276) 154 (91–248) NS
Intra 386 (207–583) 509 (374–740)
HCV RNA, median (IQR), log IU/mL a Pre 5.8 (5.5–6.0) 4.4 (3.2–4.9) NS
Intra 5.8 (5.6–5.9) 4.92 (3.6–5.0)
HIV RNA, median (IQR), log copies/mL b Pre 4.5 (3.9–5.1) 5.0 (4.1–5.4) NS
Intra ND 3.5 (3.0–4.1)
ND: no detectable.
a Bayer VERSANTs HCV RNA 3.0 Assay, range of 615–7,690,000 IU/mL).
b VERSANT HIV-1 RNA version 3.0 bDNA Assay, Siemens Diagnostics range of 50–500,000 copies/mL.
n Student t test, NS: not signiﬁcant.
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Fig. 1. Maximum likelihood tree of the 102 HCV E2 characterized from 21 HIV coinfected patients during the 7.6 years longitudinal study. It was obtained by PhyML3.0 using
GTRþΓþ I as a model of nucleotide substitution as recommended by ModelTest 3.07 (Akaike Information Criterion). The sequences from each patient are numbered
consecutively according to their sampling time. Reference sequences were named after their GenBank accession number and genotype/subtype. The numbers below the
branches represent bootstrap support values (over 1000 pseudoreplicates).
Fig. 2. Amino acid substitution patterns of hepatitis C virus (HCV) quasispecies studied in hypervariable regions of E2 (384–455). Four sequence logo (http://weblogo.
berkeley.edu) representations based on sequence alignments from HAART-responders (upper paired logos) and non-responders (lower paired logos) are shown. For each
condition, data were obtained by analyzing direct E2 amino acid sequences obtained before HAART initiation (“Baseline”) and at the latest sampling point during therapy
(“Intra”). Consensus amino acid sequences are displayed on top of the graph, and the rest of amino acids recorded in the input sequence alignment appear below. The height
of each letter indicates the relative frequency of the corresponding amino acid residue at each position. The overall height of the stack indicates sequence conservation, in
bits. Amino acid positions exhibiting the highest levels of variation are shaded.
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Analyses based on E2 nucleotide sequences obtained by cloning
Regardless of the efﬁcacy of HAART in terms of either immuno-
logical or virological response, HCV quasispecies showed similar
patterns of evolution as indicated by the coalescent analysis. Dated
maximum clade credibility trees showed that viral lineages could be
detected along varying time periods (Fig. 4 and Supplementary
Fig. 1). Fig. 4 displays the chronogram corresponding to patient 6,
including a variety of such situations. The clade in red corresponds
to a lineage that could be detected at all sampling times; i.e.
persisted along the entire follow up. In contrast with the lineage
in green, in Fig. 4 it was detected just at the beginning of the follow
up. Intermediate situations were observed as well, such as the
example the clade in blue in Fig. 4, which seems to have emerged
around 95 months before the last sampling time and gone extinct
around 45 months later. The viral populations from patients 1, 2, 5,
18 and 23 showed equivalent evolutionary patterns (Supplementary
Fig. 1). This process was also observed at amino acid levels, where,
at each time, at least two sequences with many amino acid
differences at HVR-1 co-existed in the same sample, except for a
HAART-experienced and responder patient (Pat2) who exhibited a
homogenous viral population with most of the clones correspond-
ing to almost identical HVR-1 amino acid sequences. However,
taking into account that this patient was followed-up for a shorter
period of time in relation to the other ones (4 vs. Z7 years;
Supplementary Table 1) but with annual sampling-time frequency,
the emergence of divergent sequences could not be ruled-out.
In agreement with this scenario of complex turnover of viral
variants, the substitution rates behind this process was relatively
high for both HAART-responder and non-responder patients (2.9
and 3.4102 sub/site/year, respectively; see also Fig. 4 and
Supplementary Fig. 1).
Taking into account the high substitution rates values inferred
by coalescent analysis, quasispecies heterogeneity-related para-
meters were also evaluated for these six patients. Based on the
analysis of a total of 778 HCV-E2 cloned sequences (Pat1:150;
Pat2: 41; Pat5:87; Pat6:187; Pat18:152; Pat23:131), quasispecies
diversity and complexity were obtained. The mean (7SD) genetic
diversity ranged from 0.0028 (70.0041) to 0.075 (70.079) subs/
site while the complexity varied from 0.403 to 1.00. These two
parameters did not show correlation with intra-host CD4 T cell
count variation (Table 3) but higher values were obtained more
frequently early after HAART initiation when the CD4 T cell counts
ongoing to increase among the four patients able to be studied
previous and during therapy (Table 4).
During HAART, four patients who experienced a more promi-
nent immune recovery (measured as increase in the CD4 T cell
count) showed a signiﬁcantly higher (p¼0.009) selective pressure
variation (measured as mean dN/dS ratio). They were the three
HAART non-responders (Pat6, 18, and 23) and one HAART respon-
der (Pat5) who also veriﬁed a 3.2 fold change in the absolute CD4 T
cell count during the follow-up (Table 3; Supplementary. Table 1).
Only two patients (Pat5, Pat18) exhibited a higher HCV viremia
level accompanying the CD4 T cell count increase (Fig. 3a).
As mentioned, after comparing the site-speciﬁc dN/dS rates by
different evolutionary models (SLAC and FEL), a positive selection
pressure was more evident among patients with higher immune
restoration after HAART initiation, however the mean dN/dS ratio
was o1, supporting the concept of positive selection at speciﬁc
positions (Table 3). The most frequently positively selected codons
were 397 and 476. In contrast, at baseline only one of them (Pat18)
showed a single site (codon 405) under positive selection. Altogether,
22 different sites across the 6 patients studied displayed evidence
of having been subjected to positive selection during the follow-up.
Table 2
HCV quasispecies heterogeneity analysis of paired sequence data.
Characteristic Group A Group B pn
Diversity (mean genetic distance7SD) 0.025 (70.004) 0.045 (70.005) 0.02
Complexity (normalized Shannon' entropy7SD) 0.75 (70.05) 0.88 (70.03) 0.03
Duration of follow-up in months, median (IQR) 84 [48–132] 102 [60–120] NS
dN/dS ratio, mean7SD 0.4070.04 0.7470.07 0.001
n Sequence results compared using the Student t-test or, the Mann–Whitney test.
Table 3
Sites under positive and negative selection previous and intra-HAART, dN/dS, complexity, diversity.
Patient/sampling
time according HAART
Number of sites under
positive selection
(aa sitesa)
Number of sites
under negative
selection
dN/dS Complexity
(as normalized
Shannon entropy) b
Diversity (as mean
genetic distance)b
(mean7SD)
CD4 T cell count b
(cell/mm3)
1 Pre 0 5 0.35 0.899 0.02270,013 307
Intra 2 (397; 476) 23 0.32 0.845 0.03270.023 202 [17–538]
2 Intra 0 2 0.41 0.817 0.00670.006 282 [152–427]
5 Pre 0 0 0.32 0.403 0.002870.0041 330
Intra 3 (397; 476; 529) 18 0.49 0.980 0.03070.028 971 [720–1069]
6 Pre 0 7 0.62 1.000 0.07570.079 223
Intra 13 (380; 397; 400; 405; 406;
425;439;447; 476; 481; 494; 501; 536)
29 0.63 0.989 0.05370.027 278 [221–396]
18 Pre 1 (405) 4 0.71 1.000 0.04570.024 200
Intra 7 (392; 397;409; 499;502;529;550) 16 0.73 0.865 0.04170.025 596 [306–740]
23 Intra 5 (392;442;506;522;539) 13 0.77 0.903 0.03470.025 243 [154–332]
HCV E2-amino acid numbering is relative to the H77 reference sequence. HAART responding patients are in shadow rows.
a Bold, underlined, and italics indicate amino acid positions within HVR1 (aa 382–410), HVR2 (aa 474–482), and HVR3 (aa 431–466), respectively.
b Intra-HAART values were calculated as mean (for diversity and complexity) or median [IQR] (for CD4 T cell count) of the values during the follow-up measured
under HAART.
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Six out of these 22 sites were located at the HVR1 region of E2, while
two were at HVR2 and two at HVR3 (Table 3). These observations
were also supported by sequence logo representations (Fig. 3).
Discussion
The long-term consequences of HAART-related changes in HCV
quasispecies variability are not known among HIV coinfected
patients. Others have studied the HCV evolution during short term
periods of HAART, and most of them were based on phenetic
approaches (Babik and Holodniy, 2003; Bernini et al., 2011;
Blackard et al., 2004; Shuhart et al., 2006; Solmone et al., 2006).
Although their ﬁndings are partially conﬂicting, two main consis-
tencies were found: a relatively low level of HCV heterogeneity
before HAART and an increase after treatment initiation. In the
present study we have analyzed the HCV quasispecies dynamics
under HAART pressure, over a period ranged from 4 to 11 years,
focusing on the E2 genomic region as the most variable due to its
interaction with the immune system (Guan et al., 2012). The
antiretroviral therapy could be considered a factor able to modify
the host-HCV interaction resulting in altered HCV-E2 sequence
evolution. For this goal, our study combines phenetic and phyloge-
netic approaches following a longitudinal sampling strategy. This
study was conducted with a homogenous population, including only
HCV genotype 1a/HIV coinfected patients divided in two groups
according to their virological response to HAART therapy. None of
these subjects had undergone any prior interferon-based anti-HCV
treatment. These subjects were analyzed for changes in immunolo-
gical, virological and HCV quasispecies evolutionary parameters.
Regardless of the antiretroviral therapy conducted to quantify
the immune restoration in HAART-responders and non-responders,
it was more pronounced among the latter group. Antiretroviral
therapy was prescribed to control HIV replication and to restore
immune function. Surprisingly, in our study we observed a more
pronounced immune restoration among non-responders than
responders to HAART. However, it is relevant to consider that our
protocol deﬁnition of HAART response was very strict, and most of
the patients included in the non-response group experienced blips
during the follow up but ﬁnally achieved viral suppression. Many
factors inﬂuence CD4 cell restoration despite optimal treatment
with fully suppressed viral replication (Aiuti and Mezzaroma, 2006)
including the hepatitis C coinfection (Antonucci et al., 2005; De
Luca et al., 2002; Greub et al., 2000). Moreover, it is necessary to
consider that the CD4 cell count in a given patient at any time is the
result of production, destruction, and trafﬁc between blood and
lymphatic tissue. Thus, taking into account that host-dependent
factors could inﬂuence the immunological response including the
cell turnover and distribution, and the low number of patients
studied may explain this paradoxical observation.
Among our patients, the overall HCV quasispecies genetic
complexity and diversity as well as the selective pressure were
signiﬁcantly higher. As it was reported, early after HAART initia-
tion several patients exhibited greater recovery of the immune
response (Corbeau and Reynes, 2011). Coincidentally, we observed
that more pronounced changes in the HCV evolution occurred
during this period. However it was not always accompanied by a
lower HAART-mediated HIV suppression and later, when a new
HCV-host equilibriumwas reached, the viral evolutionary dynamic
was similar to the pre-HAART stage. However, this observation
came from a small number of patients and further research is
needed before deﬁnite conclusions can be drawn. Furthermore,
these ﬁndings could be associated with HAART-related changes in
T cell functions and consequently with the magnitude of the
immune pressure, but not just with changes in T cell number
(Shuhart et al., 2006). Another limitation of the present study is
the general lack of functional immunologic data considering that
we used increased CD4 cell counts as a surrogate marker of
immune reconstitution. Even though, in the vast majority of this
study population, the long term HAART did not appear to
inﬂuence HCV replication measured as plasma viral load which
was steadily high. These results are in contradiction with those
Table 4
Intra-host variations in the hepatitis C virus quasispecies heterogeneity-related parameters during the follow-up.
Pat1
Time (months) 0 12 23 35 44 50 65 77
CD4 T cell count (cells/mL) 307 17 86 161 202 332 538 400
Complexity (as normalized Shannon entropy) 0.899 0.917 0.832 0.810 0.845 0.809 0.899 0.802
dN/dS 0.35 0.6 0.3 0.21 0.29 0.32 0.25 0.32
Diversity as mean genetic distance
(mean7SD)
0.02270.013 0.0470.038 0.0270.012 0.03170.023 0.04270.025 0.03970.03 0.02170.012 0.03170.023
Pat5
Time (months) 0 12 24 48 57 71
CD4 T cell count (cells/mL) 330 350 560 720 971 1069
Complexity (as normalized Shannon entropy) 0.403 0.996 0.991 0.975 0.942 0.992
dN/dS 0.32 0.8 0.69 0.45 0.15 0.31
Diversity as mean genetic distance
(mean7SD)
0.00370.004 0.05370.024 0.0570.022 0.03170.026 0.01770.023 0.0270.022
Pat6
Time (months) 12 0 7 18 20 37 79 91
CD4 T cell count (cells/mL) NA 142 NA NA NA 752 952 1055
Complexity (as normalized Shannon entropy) 1.000 1.000 1.000 1.000 0.981 0.982 1.000 0.981
dN/dS 0.63 0.8 0.52 0.47 0.79 0.58 0.62 0.65
Diversity as mean genetic distance
(mean7SD)
0.02670.014 0.08170.033 0.05570.024 0.05370.029 0.07770.044 0.07570.079 0.03570.02 0.04170.024
Pat18
Time (months) 0 24 48 63 73 87 108
CD4 T cell count (cells/mL) 200 306 463 740 619 573 651
Complexity (as normalized Shannon entropy) 1.000 1.000 0.896 0.874 0.885 0.852 0.702
dN/dS 0.71 1.42 0.91 0.56 0.59 0.63 0.29
Diversity as mean genetic distance
(mean7SD)
0.01670.01 0.06870.031 0.06870.038 0.05970.035 0.01170.008 0.04570.024 0.02670.027
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Fig. 3. (a) The dN/dS ratio (short dashed line), CD4 T cell count (continuous line; cell/mm3), HCV plasma viral load (long dashed line, log IU/mL 100) and HIV plasma viral
load (dotted line, log copies/mL100) dynamics during the study follow-up (expressed in months) for patient 1 (upper) and patient 18 (lower). (b) Four sequence logos are
presented for partial E2 amino acid sequences (amino acid 384–437) obtained at both, pre and intra-HAART sampling times from these two patients. At intra-patient level,
residues with signiﬁcant differences in their frequency between the two datasets are shaded.
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published elsewhere (Bernini et al., 2011; Chung et al., 2002) that
reported signiﬁcant lower HCV viral load levels at baseline.
Hence, the vigor of the immune response may drive both the
degree of HCV complexity and diversity during an ongoing process
of continuous selection and the adaptation of the virus population
in HAART virological non-responders. In contrast, the quasispecies
dynamics in HAART virological responders seemed to be limited,
probably by the need to maintain the deﬁned E2 properties.
Therefore, the HCV genotype 1a evolving in different HIV coinfected
patients, each with their genetic background, presents a different
evolutionary pattern apparently modulated by the adaptive
immune response which is modiﬁed by the antiretroviral therapy.
To better understand the HCV evolutionary process, a phylo-
genetic approach was performed using cloned E2 sequences in
order to analyze the dynamics of viral variants at intra-host level
over time. This approach was carried out by applying the coales-
cent theory to dated phylogenies that allowed estimating the rate
of evolution of the E2 gene and reconstructing its trees on a real
time scale using molecular clock models. Complex interactions
among viral variants that coexist in each patient were recognized
after the analysis of the time-annotated trees. In general, and
irrespectively of the HAART response, our analysis showed the
persistence of some variants along the infection, but also that new
variants were generated continuously in HIV-coinfected patients
on antiretroviral therapy. These new variants showed either
ulterior increase and dominance, or decrease and extinction. Such
complex evolutionary scenarios could represent the impact of the
host background on virus evolution, including HAART history and
response but in some cases also could correspond to aleatory
factors such as genetic drift. Most of the study population showed
an emerging continuous process of new mutants, but in a HAART-
experienced and responder patient, the HCV-1a probably reached
an equilibrium point where immune evasion was not necessary, as
most of the sequences cloned presented identical HVR-1 amino
acid sequences. Hence, there is evidence that the HCV quasispecies
could be related with increased HCV replication in HAART-treated
individuals, though published studies have provided conﬂicting
results (Caudai et al., 2005; Chung et al., 2002; Sherman et al.,
2005; Solmone et al., 2006). The coalescent analysis showed a very
rapid intra-host evolutionary rate regardless of the immunological
response to HAART (3.1102 sub/site/year). It appears higher
than controls without HIV-coinfection (Gray et al., 2011). However,
Fig. 4. Bayesian dated tree obtained from patient 6 sequences. The colors applied to some clades indicate lineages that persisted along the entire follow up (red), were
observed at some sampling times (blue) or were detected just in one moment along the study (green).
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it is well known that the reported estimation of HCV molecular
evolution has been highly variable being inappropriate to compare
directly due to the different methodologies, non-homogeneous
populations and genome regions employed.
Based on an intra-host analysis, the HCV quasispecies evolution
showed either complete or partial qualitative shifts in their com-
position after HAART-induced restoration of the immune pressure
and HIV-suppression. This oscillatory variations of the HCV quasis-
pecies diversity during the course of infection was already reported
among HCV monoinfected (Ramachandran et al., 2011) and HCV–
HIV coinfected subjects (Babik and Holodniy, 2003).
Despite the limited number of patients included in this study,
only a small median increased was observed without a signiﬁcant
association with either virological or immunological response or
changes in HCV heterogeneity parameters. After measuring the HCV
quasispecies diversity and complexity over time, we found no
signiﬁcant differences during the follow-up with various levels of
CD4þ T cell counts, HAART initiation, and dissimilar therapy-
mediated HIV suppression. Disparate ﬁndings were reported in
other longitudinal studies either with similar (Babik and Holodniy,
2003; Solmone et al., 2006) or contrasting results (Blackard et al.,
2004). However, these studies involved substantially shorter times
of follow-up, and several similarities in their ﬁndings appeared as
“snapshots” during our longitudinal observations. For instance,
while the intra-host immune selection pressure measured as mean
dN/dS ratio during the follow-up was o1 for HVR-1, indicating a
neutral selection pressure, the dynamics of this dN/dS ratio showed
events of positive selection pressures acting on this region after
HAART initiation for some individuals. The majority of the sites
under positive selection identiﬁed here were located in the HVR1.
This region contains epitopes targeted by neutralizing antibodies
and that may also act as epitopes for helper and cytotoxic T cells
(Wahid and Dubuisson, 2013; Wang et al., 2011). Several HVR1
amino acid variations were uniformly found in all HCV sequences
on the second microdomain intended to function as immunological
decoys to shield more conserved neutralization epitopes; instead,
the other two microdomains were more randomly distributed.
Finally, our work demonstrates that HCV quasispecies undergo
very rapid evolution in HAART-treated patients thus increasing
their complexity and diversity following the recovery of the host
immunocompetence irrespectively of the virological response to
HAART. However, a much larger study population involving
diverse hepatitis outcomes would be needed in order to ﬁnd out
whether the viral evolutionary process, as a reﬂection of the host
immune response, really drives the outcome of chronic liver
disease in persistent HCV/HIV coinfection.
Material and methods
Selection of patients
Twenty-one patients were chosen retrospectively from the
database of patients followed up at the Instituto de Investigaciones
Biomédicas en Retrovirus y Sida, Buenos Aires. These patients were
previously identiﬁed as seropositive for both HIV and HCV, infected
with HCV-genotype (Gt) 1a, and with persistently detectable HCV
RNA. None of them were treated with anti-HCV interferon plus
ribavirin-based therapy during the entire follow-up (Quarleri et al.,
2007). They could be differentiated based on HAART virological
response during the entire follow-up (Raymond et al., 2014):
(A) subjects achieving sustained optimal virological responses to
HAART with undetectable HIV-1 RNA (HAART responders; n¼12);
and (B) subjects exhibiting at least one episode of detectable HIV-1
RNA (HAART-non-responders; n¼9) (Table 1). Samples were col-
lected annually during the course of routine clinical follow-up and
stored at 80 1C until use. For each patient, we tested plasma
samples collected longitudinally across at least 4 to 11 years,
beginning at the earliest time-point before HAART initiation. The
protocol used was evaluated and approved according to the ethical
guidelines of the 1975 Declaration of Helsinki by the Fundación
Huésped Ethics Board Committee.
Ampliﬁcation and direct sequencing of HCV-E2 gene
Viral RNA was isolated from plasma samples with Trizol LS
following the manufacturer instructions (GIBCO, Life Technologies,
USA). The HCV-E2 encoding sequence was ampliﬁed using primers
EF1 (50CACTGGACCACCCAGGATTGCA30, position 1171–1196) and
E2R1 (50TGAACAGTACCGGGTTCACCAA 30, position 1947–1967),
and then primers E2F2 (50CACTGGGGTGTCCTCGTGGG 30, position
1356–1375) and E2R2 (50TGGATGAACAGTACCGGGTTCA30, position
2037–2058) in a nested reverse transcriptase polymerase chain
reaction (RT-PCR) generating a 660 bp amplicon. The RT program
included 60 min at 50 1C followed by enzyme deactivation at 85 1C
for 5 min. The ﬁrst PCR program included 35 cycles each of 30 s
(s) at 94 1C, 45 s at 54 1C and 2 min at 72 1C using a Taq DNA
polymerase (Invitrogen, Argentina), followed by a ﬁnal extension
at 72 1C for 10 min. The PCR product was used in the nested PCR
and the program included 35 cycles of 30 s at 94 1C, 30 s at 58 1C,
1 min at 72 1C and a ﬁnal extension of 72 1C for 10 min. PCR
products were resolved by electrophoresis on 1% agarose gels, and
the nested-PCR products were directly subjected to double-
stranded sequence analysis with dye-labeled dideoxy terminators
with both E2F and E2R primers (ABI PRISM 3100 automated
sequencer, Applied Biosystems, Foster City, CA, USA), obtaining
the quasispecies master sequence, or most-commonly-observed
sequence (Cabot et al., 1997; Jones et al., 2002).
Cloning, plasmid puriﬁcation and sequencing of HCV-E2 gene
A clone-based analysis was carried out on samples collected at
all sampled time-points from six randomly selected individuals
including HAART-responders (Pat1, Pat2, Pat5) and HAART-non-
responders (Pat6, Pat18, and Pat23). Each puriﬁed envelope frag-
ment was ﬁrst ligated into the pGEM-T plasmid (Easy vector,
Promega, Wisconsin, USA) according to the user manual and the
generated construct (pGEM-T-E2) was used to transform DH5α
Escherichia coli competent cells. Approximately 20 clones were
selected at each time point from each patient for sequence analysis.
White colonies were conﬁrmed by colony PCR, and PCR-positive
ones were subjected to small-scale plasmid preparation using the
GeneJet plasmid DNA miniprep kit (Thermoﬁsher Scientiﬁc, USA).
The puriﬁed plasmid was subjected to automated sequencing from
both directions using the HCV-E2 sequence speciﬁc forward (EF2)
and reverse (ER2) primers. The obtained sequences were submitted
to GenBank (accession numbers to be given).
Phylogenetic analysis of HCV-E2 nucleotide sequences
The E2 quasispecies master sequences determined by direct
sequencing as well as those obtained after molecular cloning from
all sampling time points were edited and assembled using
Sequencher software v.4.10.1 (Gene Codes Corporation, Ann Arbor,
MI USA) and aligned using Mafft program (Katoh et al., 2009).
Maximum likelihood phylogenetic trees were performed for E2
nucleotide sequences obtained directly from each patient through-
out the longitudinal study. Maximum-likelihood phylogenies were
inferred with PhyML (Guindon et al., 2009). A general time
reversible (GTR) model of nucleotide evolution and gamma-
distributed rate variation among sites were set, with molecular
clock not enforced. A total of 1000 bootstrap replicates were
M. Sede et al. / Virology 471-473 (2014) 19–2826
performed to assess the statistical support for the topologies. Trees
were visualized and annotated in FigTree v.1.3 and rooted according
to the “best root” option in Pathogen v.1.2 (http://tree.bio.ed.ac.uk/
software/pathogen). For the purposes of HCV subtyping, patients
sequences were aligned with nine HCV reference sequences
retrieved from the GenBank database (accession numbers in brack-
ets): HCV1a (M62321); HCV1b (D10074); HCV2a (AF238484);
HCV2b (D10988); HCV3a (D14311); HCV3b (D49374); HCV4a
(Y11604); HCV5a (Y13184); and HCV6a (Y12083).
Evolutionary rate estimation and demographic analysis
Bayesian coalescent analysis was performed with the BEAST
program (Drummond and Rambaut, 2007). Six different HCV-E2
sequences datasets were used for Bayesian coalescent analyses.
Each of them contained all of the sequences obtained by molecular
cloning from each selected patient and time points.
Evolutionary rates were estimated using a relaxed molecular
clock model. We compared the constant size demographic model
against the Bayesian Skyline Plot (BSP) one using a Bayes factor
approach, which favored decisively a constant population size.
The obtained Bayes factors were 682, 20, 113, 5, 224 and 75 for the
sequences corresponding to patients 1, 2, 5, 6, 18 and 23,
respectively. Thus, the model employed to reconstruct trees and
calculate evolutionary rate implemented a constant population
size. The MCMC chains were run for at least 100 million genera-
tions, and sampled every 10,000 steps. Convergence was assessed
on the basis of the effective sampling size (ESS) after a 10% burn-in
using Tracer software version 1.3 (http://tree.bio.ed.ac.uk/soft
ware/tracer/). Only ESSs of 4200 were accepted. Uncertainty in
the estimates was indicated by 95% HPD intervals. The trees were
summarized with a maximum clade credibility tree using the Tree
Annotator program included in BEAST after discarding the burnin
samples. This tree was then visualized using the program FigTree
1.2 (available at http://tree.bio.ed.ac.uk/software/ﬁgtree/).
HCV quasispecies heterogeneity and site-speciﬁc selection pressure
analyses
The amino acid sequences of HCV-E2 protein were analyzed
to assess both inter- and intra-patient quasispecies heterogen-
eity dynamics during the follow-up. Such analysis involved:
(i) complexity, measured as normalized Shannon entropy (Pawlotsky
et al., 1998); (ii) diversity, as the mean genetic distance of amino acid
sequences calculated by PROTDIST using Jones–Taylor–Thornton
matrix [http://caps.ncbs.res.in/iws/protdist.html]; (iii) the dN/dS ratio
(as a surrogate indicator for immune pressure) according to the Nei–
Gojobori method with the Jukes–Cantor correction (Nei and Gojobori,
1986) by using the Synonymous Non-synonymous Analysis Program
(SNAP v1.1.1)(Korber, 2000) [www.hiv.lanl.gov]; and (iv) positive
selection using the single likelihood ancestor counting (SLAC) and
the Fixed Effects Likelihood (FEL) methods that enable detection of
non-neutral selection. These methods were chosen for their applic-
ability to large (450 taxa) datasets and short sequences. The Hyphy
software was used for these analyses (http://www.datamonkey.org/)
(Pond et al., 2005). Only sites that were identiﬁed by SLAC (pr0.05
signiﬁcance) were included in the ﬁnal result (Kosakovsky Pond and
Frost, 2005). The presence of recombination events was investigated
using GARD, a genetic algorithm implemented in Datamonkey to
identify non-recombinant fragments; recombinant sequences were
excluded from the subsequent analyses.
E2-amino acid frequency analysis and qualitative mutational analysis
The relative amino acid frequencies at each E2 position were
represented by sequence logo. To this aim a web based application
was used (http://weblogo.berkeley.edu) that allows distinguishing
residue frequency differences between two given datasets (in our
case, HCV E2 amino acid sequences at baseline and at the latest
sampling time for each group of patients) (Crooks et al., 2004).
To further evaluate the importance of the identiﬁed E2 amino acid
exchanges, an analysis was conducted according to their functional
properties. The properties under analysis included the three func-
tional HVR1 microdomains (Guan et al., 2012; Wang et al., 2011).
Statistical analysis
Statistical analysis of quantitative variables was performed
using the Student t test. Differences between mean genetic
distances were assessed using non-parametric Kruskal–Wallis's
and Dunn's multiple-comparison tests. Correlations between
virological, immunological and quasispecies parameters were
evaluated by Spearman's coefﬁcient. A p valueo0.05 was con-
sidered signiﬁcant. All the analyses were performed with SPSS
version 12.0 (SPSS, Inc., Chicago, IL).
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